Elicera cleared to use highest ELC-301 dose before Phase IIa
Elicera Therapeutics AB received clearance to use the highest ELC-301 dose ahead of Phase IIa.
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Elicera Therapeutics AB received clearance to use the highest ELC-301 dose ahead of Phase IIa.